Home

Alicia Secor

CIK 1584516 · President and CEO · last filed 2026-06-18

Alicia Secor is a President and CEO who has filed 32 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing, for ZVRA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

7

Total Filings

32

Lifetime Open-Market Net

-$1.09M

Filer Profile

Reported Address
1180 CELEBRATION BLVD., SUITE 103
CELEBRATION, FL 34747
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ZVRA Director — $12.40 — $0 2 2026-06-18
G1 Therapeutics, Inc. (GTHX) Delisted Director 0 $7.15 $0 $0 5 2024-09-18
Orchard Therapeutics plc (ORTX) Delisted Director — $16.70 — $0 5 2024-01-24
GW PHARMACEUTICALS PLC (GWPH) Delisted Director 11,844 $218.96 $2.59M -$36.7K 9 2021-03-02
JUNIPER PHARMACEUTICALS INC (JNP) Delisted President and CEO 0 — — $28.8K 6 2018-08-15
Larimar Therapeutics, Inc. (ZFGN) Delisted Chief Commercial Officer 438 — — -$1.08M 3 2016-04-04
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted SVP, Chief Operating Officer — — — $0 1 2013-09-23

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 ZVRA Grant (A) — $0 EDGAR
2025-12-09 ZVRA Grant (A) — $0 EDGAR
2024-09-18 G1 Therapeutics, Inc. (GTHX) Delisted Mixed −30,000 $0 EDGAR
2024-06-14 G1 Therapeutics, Inc. (GTHX) Delisted Grant (A) +10,000 $0 EDGAR
2024-01-24 Orchard Therapeutics plc (ORTX) Delisted Disp (D) — $0 EDGAR
2023-06-16 G1 Therapeutics, Inc. (GTHX) Delisted Grant (A) +10,000 $0 EDGAR
2023-06-16 Orchard Therapeutics plc (ORTX) Delisted Grant (A) — $0 EDGAR
2022-06-24 G1 Therapeutics, Inc. (GTHX) Delisted Grant (A) +10,000 $0 EDGAR
2022-06-08 Orchard Therapeutics plc (ORTX) Delisted Grant (A) — $0 EDGAR
2021-06-21 G1 Therapeutics, Inc. (GTHX) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.